SG11202106353VA - Novel fusion proteins specific for cd137 and gpc3 - Google Patents

Novel fusion proteins specific for cd137 and gpc3

Info

Publication number
SG11202106353VA
SG11202106353VA SG11202106353VA SG11202106353VA SG11202106353VA SG 11202106353V A SG11202106353V A SG 11202106353VA SG 11202106353V A SG11202106353V A SG 11202106353VA SG 11202106353V A SG11202106353V A SG 11202106353VA SG 11202106353V A SG11202106353V A SG 11202106353VA
Authority
SG
Singapore
Prior art keywords
gpc3
fusion proteins
proteins specific
novel fusion
novel
Prior art date
Application number
SG11202106353VA
Inventor
Aiba Rachida Siham Bel
Birgit Bossenmaier
Thomas Jaquin
Janet Peper-Gabriel
Eva-Maria Hansbauer
Corinna Schlosser
Shane Olwill
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of SG11202106353VA publication Critical patent/SG11202106353VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG11202106353VA 2019-02-26 2020-02-25 Novel fusion proteins specific for cd137 and gpc3 SG11202106353VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19000100 2019-02-26
PCT/EP2020/054821 WO2020173897A1 (en) 2019-02-26 2020-02-25 Novel fusion proteins specific for cd137 and gpc3

Publications (1)

Publication Number Publication Date
SG11202106353VA true SG11202106353VA (en) 2021-07-29

Family

ID=65685094

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106353VA SG11202106353VA (en) 2019-02-26 2020-02-25 Novel fusion proteins specific for cd137 and gpc3

Country Status (12)

Country Link
US (1) US20220153864A1 (en)
EP (1) EP3931209A1 (en)
KR (1) KR20210133254A (en)
CN (1) CN113474359A (en)
AU (1) AU2020229436A1 (en)
BR (1) BR112021016829A2 (en)
CA (1) CA3124441A1 (en)
IL (1) IL284687A (en)
MA (1) MA55069A (en)
MX (1) MX2021010039A (en)
SG (1) SG11202106353VA (en)
WO (1) WO2020173897A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216744A2 (en) * 2021-04-05 2022-10-13 Cytovia Therapeutics, Llc. Bispecific antibodies targeting nkp46 and gpc3 and methods of use thereof
EP4326780A1 (en) * 2021-04-23 2024-02-28 Shanghai Henlius Biotech, Inc. Anti-gpc3 antibodies, multispecific antibodies and methods of use
EP4341294A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
WO2023036043A1 (en) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 Anti-cancer binding molecule and use thereof
CN113912699A (en) * 2021-10-14 2022-01-11 江南大学 Novel FGF analogue for treating breast cancer and application thereof
CN113956344A (en) * 2021-10-14 2022-01-21 江南大学 Novel FGF analogue for treating liver cancer and application thereof
CN116640224A (en) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Fusion protein of CD137 antibody and CD40L and application thereof
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (en) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk Production of normal human serum albumin a through gene recombination
FR2649991B2 (en) 1988-08-05 1994-03-04 Rhone Poulenc Sante USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
EP1087778B1 (en) 1998-06-08 2005-10-26 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4336771B2 (en) 2001-03-09 2009-09-30 モルフォシス アーゲー Serum albumin binding moiety
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
MA40764A (en) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
SG11201708334RA (en) * 2015-05-04 2017-11-29 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
ES2938525T3 (en) * 2015-05-18 2023-04-12 Pieris Pharmaceuticals Gmbh Anticancer Fusion Polypeptide
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3565595A4 (en) * 2017-01-06 2021-03-17 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
JP7282383B2 (en) * 2017-06-14 2023-05-29 ディンフー バイオターゲット カンパニー リミテッド Proteinaceous heterodimer and use thereof

Also Published As

Publication number Publication date
WO2020173897A1 (en) 2020-09-03
EP3931209A1 (en) 2022-01-05
JP2022523524A (en) 2022-04-25
MX2021010039A (en) 2021-09-21
IL284687A (en) 2021-08-31
CN113474359A (en) 2021-10-01
AU2020229436A1 (en) 2021-07-01
KR20210133254A (en) 2021-11-05
US20220153864A1 (en) 2022-05-19
CA3124441A1 (en) 2020-09-03
MA55069A (en) 2022-01-05
BR112021016829A2 (en) 2021-10-19

Similar Documents

Publication Publication Date Title
IL284687A (en) Novel fusion proteins specific for cd137 and gpc3
ZA202100125B (en) Novel fusion protein specific for cd137 and pd-l1
IL273439A (en) Fusion proteins comprising enzyme replacement therapy enzymes
IL276469A (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
EP3275895A4 (en) Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof
IL289887A (en) Fusion polypeptide for immunotherapy
IL287318A (en) Materials and methods for protein production
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
EP4083055A4 (en) Sugar-modified protein
IL290660A (en) Therapeutic fusion proteins
SG11202000775SA (en) Fusion tags for recombinant protein expression
IL304317A (en) Tgf-beta-rii binding proteins
GB201919294D0 (en) Antibodies or binding proteins
IL290715A (en) Nkg2d fusion proteins and uses thereof
GB201816873D0 (en) Fusion protein
IL287928A (en) Variant domains for multimerizing proteins and separation thereof
IL286419A (en) Novel selection marker-comprising cell line and uses thereof for protein production
EP4100444A4 (en) Mucin-binding fusion proteins
EP3997231A4 (en) Methods for making recombinant protein
PT3830120T (en) Novel fusion protein specific for cd137 and pd-l1
GB201913320D0 (en) Novel proteins
EP4031583A4 (en) Chimeric receptor proteins and uses thereof
GB201904756D0 (en) Novel proteins
AU2019900678A0 (en) Modified binding proteins
GB201909710D0 (en) Proteins